15 результати
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
BACKGROUND OF THE INVENTION
Apoptosis, or programmed cell death (PCD), is a genetically regulated mechanism with a central role in both metazoan development and homeostasis. (Raff, 1992; Steller, 1995). The cell death machinery is conserved throughout evolution (Vaux et al., 1994) and is composed of
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a process for manufacturing soybean proteins and, more particularly, to a process for manufacturing soybean proteins particularly suitable as edible proteins.
2. Description of the Prior Art
Heretofore, processes
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, G, R.sup.10, R.sup.11, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for
This application claims the benefit of European Application No. EP13305402.3, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety.
The present invention relates to compounds of the formula I,
##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,
This application claims the benefit of European Application No. EP13305401.5, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety.
The present invention relates to compounds of the formula I,
##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,
The present invention relates to compounds of the formula I,
##STR00002## wherein Ht, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
The present invention relates to compounds of the formulae Ia and Ib,
##STR00002## wherein R1, R2, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are